Charles Schwab Investment Management Inc Inozyme Pharma, Inc. Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 45,182 shares of INZY stock, worth $180,728. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45,182
Previous 122,290
63.05%
Holding current value
$180,728
Previous $111,000
62.16%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding INZY
# of Institutions
87Shares Held
51.9MCall Options Held
162KPut Options Held
0-
Beryl Capital Management LLC Redondo Beach, CA6.32MShares$25.3 Million3.83% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$18 Million16.98% of portfolio
-
Glazer Capital, LLC New York, NY4.33MShares$17.3 Million0.62% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$17.1 Million1.16% of portfolio
-
Black Rock Inc. New York, NY3.34MShares$13.4 Million0.0% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $161M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...